1312 related articles for article (PubMed ID: 26246574)
1. Virus-Like Vesicle-Based Therapeutic Vaccine Vectors for Chronic Hepatitis B Virus Infection.
Reynolds TD; Buonocore L; Rose NF; Rose JK; Robek MD
J Virol; 2015 Oct; 89(20):10407-15. PubMed ID: 26246574
[TBL] [Abstract][Full Text] [Related]
2. A Highly Attenuated Vesicular Stomatitis Virus-Based Vaccine Platform Controls Hepatitis B Virus Replication in Mouse Models of Hepatitis B.
Moshkani S; Chiale C; Lang SM; Rose JK; Robek MD
J Virol; 2019 Mar; 93(5):. PubMed ID: 30541859
[TBL] [Abstract][Full Text] [Related]
3. Heterologous prime-boost immunization with vesiculovirus-based vectors expressing HBV Core antigen induces CD8
Chiale C; Moshkani S; Rose JK; Robek MD
Antiviral Res; 2019 Aug; 168():156-167. PubMed ID: 31153968
[TBL] [Abstract][Full Text] [Related]
4. A vesicular stomatitis virus-based therapeutic vaccine generates a functional CD8 T cell response to hepatitis B virus in transgenic mice.
Cobleigh MA; Wei X; Robek MD
J Virol; 2013 Mar; 87(5):2969-73. PubMed ID: 23269785
[TBL] [Abstract][Full Text] [Related]
5. Elimination of immunodominant epitopes from multispecific DNA-based vaccines allows induction of CD8 T cells that have a striking antiviral potential.
Riedl P; Wieland A; Lamberth K; Buus S; Lemonnier F; Reifenberg K; Reimann J; Schirmbeck R
J Immunol; 2009 Jul; 183(1):370-80. PubMed ID: 19542448
[TBL] [Abstract][Full Text] [Related]
6. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
[TBL] [Abstract][Full Text] [Related]
7. Evaluating replication-defective vesicular stomatitis virus as a vaccine vehicle.
Majid AM; Ezelle H; Shah S; Barber GN
J Virol; 2006 Jul; 80(14):6993-7008. PubMed ID: 16809305
[TBL] [Abstract][Full Text] [Related]
8. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
9. A vesicular stomatitis virus-based hepatitis B virus vaccine vector provides protection against challenge in a single dose.
Cobleigh MA; Buonocore L; Uprichard SL; Rose JK; Robek MD
J Virol; 2010 Aug; 84(15):7513-22. PubMed ID: 20504927
[TBL] [Abstract][Full Text] [Related]
10. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
11. Functional aspects of intrahepatic hepatitis B virus-specific T cells induced by therapeutic DNA vaccination.
Brass A; Frelin L; Milich DR; Sällberg M; Ahlén G
Mol Ther; 2015 Mar; 23(3):578-90. PubMed ID: 25492563
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
[TBL] [Abstract][Full Text] [Related]
13. Knockdown of Virus Antigen Expression Increases Therapeutic Vaccine Efficacy in High-Titer Hepatitis B Virus Carrier Mice.
Michler T; Kosinska AD; Festag J; Bunse T; Su J; Ringelhan M; Imhof H; Grimm D; Steiger K; Mogler C; Heikenwalder M; Michel ML; Guzman CA; Milstein S; Sepp-Lorenzino L; Knolle P; Protzer U
Gastroenterology; 2020 May; 158(6):1762-1775.e9. PubMed ID: 32001321
[TBL] [Abstract][Full Text] [Related]
14. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
[TBL] [Abstract][Full Text] [Related]
15. [Immunological and virological efficacy against HBV chronic infection of the therapeutic vaccine composed of HBV core plus PreS1 in HBV transgenic mice].
Li MZ; Chen XC; Zhou BP; Le XH; Xu LM; Wang HS
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2003 Sep; 17(3):277-9. PubMed ID: 15340577
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus core and e antigen: immune recognition and use as a vaccine carrier moiety.
Schödel F; Peterson D; Milich D
Intervirology; 1996; 39(1-2):104-10. PubMed ID: 8957676
[TBL] [Abstract][Full Text] [Related]
17. Immune responses to recombinant Mycobacterium smegmatis expressing fused core protein and preS1 peptide of hepatitis B virus in mice.
Yue Q; Hu X; Yin W; Xu X; Wei S; Lei Y; Lü X; Yang J; Su M; Xu Z; Hao X
J Virol Methods; 2007 Apr; 141(1):41-8. PubMed ID: 17197041
[TBL] [Abstract][Full Text] [Related]
18. A novel HBV DNA vaccine based on T cell epitopes and its potential therapeutic effect in HBV transgenic mice.
Li X; Yang X; Jiang Y; Liu J
Int Immunol; 2005 Oct; 17(10):1293-302. PubMed ID: 16113237
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity and tolerogenicity of hepatitis B virus structural and nonstructural proteins: implications for immunotherapy of persistent viral infections.
Kakimi K; Isogawa M; Chung J; Sette A; Chisari FV
J Virol; 2002 Sep; 76(17):8609-20. PubMed ID: 12163580
[TBL] [Abstract][Full Text] [Related]
20. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
